Circulating and Tissue Galectin-3 in Gastrointestinal Inflammation: Clinical Significance and Biomarker Potential
Cells · 29.09.2025 · 14 (19) · 1521
DOI: 10.3390/cells14191521 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 29.09.2025. Verfasst von Vesna Brzački und 8 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Hepatology Clinic, University Clinical Center Niš, 18000 Niš, Serbia. Hauptthemen laut MEDLINE: Galectin 3, Gastroenteritis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Galectins represent a family of widely expressed lectins that have the ability to bind β-galactoside in modulating “cell-to-cell” and “cell-to-matrix” interactions in all organisms. These proteins are expressed in many inflammatory cells, such as macrophages, and depending on the inflammatory environment, they promote pro-inflammatory or anti-inflammatory responses. Galectin-3 (Gal-3) is predominantly located in the cytoplasm, but, as noted, it has also been detected in the nucleus, on the cell surface and in the extracellular environment, which indicates the multifunctionality of this molecule. It has been shown in many studies that Gal-3 is involved in immune regulation, fibrosis, and tissue remodeling, making it an important player in disorders such as inflammatory bowel disease (IBD), non-alcoholic steatohepatitis (NASH), and liver fibrosis. In IBD, this protein is associated with activation of the NLRP3 inflammasome, contributing to chronic intestinal inflammation. Also, in primary biliary cholangitis and autoimmune hepatitis, Gal-3 potentiate development of fibrosis through fibroblast-to-myofibroblast transition and extracellular matrix deposition, while in liver fibrosis, it is upregulated in hepatic stellate cells and macrophages, promoting fibrosis and inflammation. Studies show that Gal-3 inhibition reduces fibrosis and inflammation, making it a promising therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastroenterology and Hepatology Clinic, University Clinical Center Niš, 18000 Niš, Serbia.
- Department of Internal Medicine, Faculty of Medicine, University of Niš, 18000 Niš, Serbia.
- Clinic for Nephrology, University Clinical Center Niš, 18000 Niš, Serbia.
- Plastic and Reconstructive Surgery Clinic, University Clinical Center Niš, 18000 Niš, Serbia.
ORCID-Profile: Andrija Rančić
Zitieren
APA
Brzački, V., Jovanović, A., Rančić, A., Tešić-Rajković, S., Petrović, G., Nagorni, I., Stojanović, M., Stanković, E., & Momčilović, S. (2025). Circulating and Tissue Galectin-3 in Gastrointestinal Inflammation: Clinical Significance and Biomarker Potential. Cells, 14(19), 1521. https://doi.org/10.3390/cells14191521
Vancouver
Brzački V, Jovanović A, Rančić A, Tešić-Rajković S, Petrović G, Nagorni I, et al. Circulating and Tissue Galectin-3 in Gastrointestinal Inflammation: Clinical Significance and Biomarker Potential. Cells. 2025;14(19):1521. doi:10.3390/cells14191521
BibTeX
@article{Brzaki2025,
author = {Brzački, Vesna and Jovanović, Andriana and Rančić, Andrija and Tešić-Rajković, Snežana and Petrović, Gordana and Nagorni, Ivan and Stojanović, Marko and Stanković, Elena and Momčilović, Stefan},
title = {Circulating and Tissue Galectin-3 in Gastrointestinal Inflammation: Clinical Significance and Biomarker Potential},
journal = {Cells},
year = {2025},
volume = {14},
number = {19},
pages = {1521},
doi = {10.3390/cells14191521}
}
EUVIMED